Who are Biological: AZD3152's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AVELUMAB, DURVALUMAB, Atezolizumab Injection [Tecentriq], Avelumab first-line maintenance, Adebrelimab combined with SOX regimen, Avelumab (MSB0010718C).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/biological-azd3152.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Biological: AZD3152 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biological: AZD3152 (Biological: AZD3152) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor. Area: Oncology.

phase 2 PD-1/PD-L1 inhibitor PD-L1 Oncology Biologic Live · refreshed every 30 min

Target snapshot

Biological: AZD3152 (Biological: AZD3152) — AstraZeneca. AZD3152 is a monoclonal antibody targeting PD-L1.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Biological: AZD3152 TARGET	Biological: AZD3152	AstraZeneca	phase 2	PD-1/PD-L1 inhibitor	PD-L1
AVELUMAB	AVELUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
DURVALUMAB	DURVALUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
Atezolizumab Injection [Tecentriq]	Atezolizumab Injection [Tecentriq]	Nykode Therapeutics ASA	marketed	PD-L1 inhibitor	PD-L1
Avelumab first-line maintenance	Avelumab first-line maintenance	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	PD-L1 inhibitor	PD-L1
Adebrelimab combined with SOX regimen	Adebrelimab combined with SOX regimen	Yang Jianjun, PhD	marketed	PD-L1 inhibitor	PD-L1
Avelumab (MSB0010718C)	avelumab-msb0010718c	Pfizer	marketed	Monoclonal antibody	PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 drugs in this class
AstraZeneca · 2 drugs in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Hanlim Pharm. Co., Ltd. · 1 drug in this class
EMD Serono · 1 drug in this class
EMS · 1 drug in this class
Fujian Cancer Hospital · 1 drug in this class
Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 drug in this class
Cellvax Therapeutics Inc · 1 drug in this class
Anhui Shi, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Biological: AZD3152 — Competitive Intelligence Brief. https://druglandscape.com/ci/biological-azd3152. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing